Jeong, Y.G.; Katuwal, N.B.; Kang, M.S.; Ghosh, M.; Hong, S.D.; Park, S.M.; Kim, S.-G.; Kim, T.H.; Moon, Y.W.
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. Cancers 2023, 15, 4887.
https://doi.org/10.3390/cancers15194887
AMA Style
Jeong YG, Katuwal NB, Kang MS, Ghosh M, Hong SD, Park SM, Kim S-G, Kim TH, Moon YW.
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. Cancers. 2023; 15(19):4887.
https://doi.org/10.3390/cancers15194887
Chicago/Turabian Style
Jeong, Yeong Gyu, Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Tae Hoen Kim, and Yong Wha Moon.
2023. "Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer" Cancers 15, no. 19: 4887.
https://doi.org/10.3390/cancers15194887
APA Style
Jeong, Y. G., Katuwal, N. B., Kang, M. S., Ghosh, M., Hong, S. D., Park, S. M., Kim, S. -G., Kim, T. H., & Moon, Y. W.
(2023). Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. Cancers, 15(19), 4887.
https://doi.org/10.3390/cancers15194887